Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.

[1]  W. Wiktor-Jedrzejczak,et al.  Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study , 2017, Leukemia.

[2]  F. Mahon,et al.  Deep molecular responses for treatment‐free remission in chronic myeloid leukemia , 2016, Cancer medicine.

[3]  J. Lipton,et al.  Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study. , 2016 .

[4]  M. Baccarani,et al.  Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Cortes,et al.  Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study. , 2016, Clinical lymphoma, myeloma & leukemia.

[6]  M. Baccarani,et al.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia , 2016, Leukemia.

[7]  I. Flinn,et al.  Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial , 2016, Leukemia.

[8]  B. Leber,et al.  Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. , 2014, Blood.

[9]  C. Keir,et al.  Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase , 2014, Current medical research and opinion.

[10]  J. Reiffers,et al.  Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy , 2014, Haematologica.

[11]  Martin C. Müller,et al.  Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Emerson,et al.  Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. , 2013, Canadian family physician Medecin de famille canadien.

[13]  F. Mahon,et al.  Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy? , 2013, Clinical Cancer Research.

[14]  Francisco Cervantes,et al.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.

[15]  C. Cleeland,et al.  Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. , 2013, Blood.

[16]  D. DeAngelo.  Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy , 2012, Blood Cancer Journal.

[17]  I. Flinn,et al.  Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up , 2012, Leukemia.

[18]  I. Flinn,et al.  Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up , 2012, Leukemia.

[19]  M. Humbert,et al.  Pulmonary Arterial Hypertension in Patients Treated by Dasatinib , 2012, Circulation.

[20]  M. Baccarani,et al.  Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). , 2012, Blood.

[21]  I. Flinn,et al.  Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. , 2011, The Lancet. Oncology.

[22]  T. Sagar,et al.  Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia , 2011, American journal of hematology.

[23]  M. Baccarani,et al.  Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. , 2011, Blood.

[24]  D. Marin,et al.  Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. , 2011, Leukemia research.

[25]  J. Radich,et al.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. , 2011, Blood.

[26]  K. Rezvani,et al.  Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. , 2010, Blood.

[27]  D. Marin,et al.  Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Cortes,et al.  Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion , 2010, Cancer.

[29]  J. Radich,et al.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. , 2008, Blood.

[30]  Gerhard Dürnberger,et al.  Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. , 2007, Blood.

[31]  K. Bhalla,et al.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. , 2007, Blood.

[32]  Branford,et al.  Monitoring chronic myeloid leukaemia therapy by real‐time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics , 1999, British journal of haematology.

[33]  S. Ghio,et al.  Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. , 2012, Leukemia research.

[34]  M. Gordon.  Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .